Cargando…

Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease

Recently, zonisamide (ZNS) has been approved as a new adjunctive therapy for motor complications of Parkinson's disease (PD). More recently, ZNS was reported to be effective for the management of impulse control behavior in PD, suggesting potential effects on non-motor PD symptoms. Dream enactm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kataoka, Hiroshi, Ueno, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335357/
https://www.ncbi.nlm.nih.gov/pubmed/22545035
http://dx.doi.org/10.1159/000336441
_version_ 1782230783284477952
author Kataoka, Hiroshi
Ueno, Satoshi
author_facet Kataoka, Hiroshi
Ueno, Satoshi
author_sort Kataoka, Hiroshi
collection PubMed
description Recently, zonisamide (ZNS) has been approved as a new adjunctive therapy for motor complications of Parkinson's disease (PD). More recently, ZNS was reported to be effective for the management of impulse control behavior in PD, suggesting potential effects on non-motor PD symptoms. Dream enactment associated with aggressive, violent behavior can carry a serious risk of injury to patients, as well as to spouses or caretakers. This report describes a patient with PD who had vivid nightmares and dream-enacting behavior that resolved after treatment with ZNS. The present case raises the question whether ZNS might potentially be effective for the management of vivid nightmares or dream-enacting behavior.
format Online
Article
Text
id pubmed-3335357
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-33353572012-04-27 Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease Kataoka, Hiroshi Ueno, Satoshi Case Rep Neurol Published: January, 2012 Recently, zonisamide (ZNS) has been approved as a new adjunctive therapy for motor complications of Parkinson's disease (PD). More recently, ZNS was reported to be effective for the management of impulse control behavior in PD, suggesting potential effects on non-motor PD symptoms. Dream enactment associated with aggressive, violent behavior can carry a serious risk of injury to patients, as well as to spouses or caretakers. This report describes a patient with PD who had vivid nightmares and dream-enacting behavior that resolved after treatment with ZNS. The present case raises the question whether ZNS might potentially be effective for the management of vivid nightmares or dream-enacting behavior. S. Karger AG 2012-01-25 /pmc/articles/PMC3335357/ /pubmed/22545035 http://dx.doi.org/10.1159/000336441 Text en Copyright © 2012 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: January, 2012
Kataoka, Hiroshi
Ueno, Satoshi
Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
title Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
title_full Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
title_fullStr Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
title_full_unstemmed Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
title_short Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson's Disease
title_sort nightmare-enacting behavior responding to zonisamide in early parkinson's disease
topic Published: January, 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335357/
https://www.ncbi.nlm.nih.gov/pubmed/22545035
http://dx.doi.org/10.1159/000336441
work_keys_str_mv AT kataokahiroshi nightmareenactingbehaviorrespondingtozonisamideinearlyparkinsonsdisease
AT uenosatoshi nightmareenactingbehaviorrespondingtozonisamideinearlyparkinsonsdisease